loading page

Tisagenlecleucel for treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia
  • Stephanie Si,
  • Stephan Grupp,
  • Amanda DiNofia
Stephanie Si
Children's Hospital of Philadelphia
Author Profile
Stephan Grupp
Children's Hospital of Philadelphia
Author Profile
Amanda DiNofia
The Children's Hospital of Philadelphia
Author Profile

Abstract

The treatment landscape for cancer therapy has changed drastically over the past decade. Tisagenlecleucel, the first genetically engineered adoptive cellular therapy approved by the United States Food and Drug Administration, has revolutionized this field by demonstrating impressive clinical success in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (r/r B-ALL). Now three years since its approval, we have gained a deeper understanding on the basic immunobiology and clinical efficacy of this drug. This review will provide an updated summary of the clinical efficacy of tisagenlecleucel in childhood and young adults with r/r B-ALL, common side effects and their associated management strategies, as well as barriers that remain to be addressed in order to realize the maximum potential of this drug.

Peer review status:ACCEPTED

18 Sep 2020Submitted to Pediatric Blood & Cancer
18 Sep 2020Submission Checks Completed
18 Sep 2020Assigned to Editor
29 Sep 2020Reviewer(s) Assigned
11 Oct 2020Review(s) Completed, Editorial Evaluation Pending
22 Oct 2020Editorial Decision: Revise Major
13 Jan 2021Assigned to Editor
13 Jan 2021Submission Checks Completed
13 Jan 20211st Revision Received
21 Jan 2021Reviewer(s) Assigned
21 Feb 2021Review(s) Completed, Editorial Evaluation Pending
21 Feb 2021Editorial Decision: Revise Minor
20 Apr 20212nd Revision Received
20 Apr 2021Submission Checks Completed
20 Apr 2021Assigned to Editor
24 Apr 2021Reviewer(s) Assigned
02 May 2021Review(s) Completed, Editorial Evaluation Pending
05 May 2021Editorial Decision: Accept